NicOx gains as glaucoma product meets Phase IIb endpoint

NicOx S.A. (Euronext:COX) gained EUR 0.82 (45%) to EUR 2.64 on Tuesday after BOL-303259-X met the primary endpoint of reducing mean diurnal intraocular pressure (IOP) from baseline to day 28 vs. Xalatan latanoprost in a Phase IIb trial to treat primary open-angle glaucoma and ocular hypertension. The single-blind, dose-ranging, international trial enrolled 413 patients. ...